Jazz Pharmaceuticals (JAZZ) Accounts Payables (2010 - 2026)

Jazz Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $100.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 4.24% year-over-year to $100.0 million in Q1 2026; TTM through Mar 2026 was $100.0 million, a 4.24% increase from a year earlier, with the FY2025 full-year figure at $122.1 million, up 56.8% from the prior year.
• Accounts Payables eased to $100.0 million in Q1 2026 per JAZZ's latest filing, from $122.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $152.2 million in Q3 2025 and bottomed at $73.3 million in Q1 2022.
• The 5-year median for Accounts Payables is $97.1 million (2024), against an average of $98.7 million.
• Across the five-year window, Accounts Payables plunged 35.45% in 2024 and jumped 78.2% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $90.8 million in 2022, then rose by 13.21% to $102.8 million in 2023, then retreated by 24.22% to $77.9 million in 2024, then soared by 56.8% to $122.1 million in 2025, then declined by 18.1% to $100.0 million in 2026.
• Per Business Quant, the three latest JAZZ Accounts Payables figures stand at $100.0 million (Q1 2026), $122.1 million (Q4 2025), and $152.2 million (Q3 2025).